<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453232</url>
  </required_header>
  <id_info>
    <org_study_id>CRCA-CCTC-ACCELERATED-BEP</org_study_id>
    <secondary_id>CDR0000537042</secondary_id>
    <secondary_id>EUDRACT-2004-000847-79</secondary_id>
    <secondary_id>EU-20713</secondary_id>
    <secondary_id>ISRCTN18505589</secondary_id>
    <nct_id>NCT00453232</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors</brief_title>
  <official_title>Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as bleomycin, etoposide, and cisplatin, work in
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping
      them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the
      number of immune cells found in bone marrow or peripheral blood and may help the immune
      system recover from the side effects of chemotherapy. Giving combination chemotherapy
      together with pegfilgrastim may kill more tumor cells.

      PURPOSE: This phase II trial is studying the side effects and how well giving combination
      chemotherapy together with pegfilgrastim works in treating men with metastatic germ cell
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility of accelerated treatment comprising bleomycin, etoposide,
           cisplatin, and pegfilgrastim in men with metastatic germ cell tumors.

        -  Determine the toxicity of this regimen (particularly with respect to renal, pulmonary,
           and neurological function) in these patients.

      Secondary

        -  Determine the response rate in patients treated with this regimen.

        -  Determine the progression-free survival of patients treated with this regimen.

      OUTLINE: This is a non-randomized, pilot study.

      Patients receive etoposide IV on days 1-3, cisplatin IV on days 1 and 2, and bleomycin IV
      over 2 hours on days 2, 6, and 10. Patients also receive pegfilgrastim subcutaneously on day
      4. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression
      or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically for 2 years.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Teratoma</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients must fulfill all of the following criteria for 1 of the following diagnoses:

               -  Nonseminoma germ cell tumor (intermediate risk)

                    -  Testis or retroperitoneal primary

                    -  Abnormal markers (alpha fetoprotein [AFP] &gt; 1,000 and &lt; 10,000 ng/mL, human
                       chorionic gonadotropin [HCG] &gt; 5,000 and &lt; 50,000 IU/L, lactate
                       dehydrogenase [LDH] &gt; 1.5 times and &lt; 10 times upper limit of normal [ULN])

                    -  No liver, bone, brain, or other nonpulmonary visceral metastasis

                    -  Histologic confirmation is not required if AFP or HCG are grossly elevated

               -  Nonseminoma germ cell tumor (poor prognosis) meeting 1 of the following criteria:

                    -  Mediastinal primary

                    -  Nonpulmonary visceral metastases

                    -  Poor markers (AFP &gt; 10,000 ng/mL, HCG &gt; 50,000 IU/L, LDH &gt; 10 times ULN)

                    -  Histologic confirmation not required if AFP or HCG are grossly elevated

               -  Seminoma (intermediate prognosis)

                    -  Histological confirmation is required

                    -  Any primary site

                    -  Nonpulmonary visceral metastases must be present

                    -  Normal AFP

                    -  Any HCG

                    -  Any LDH

               -  Surveillance relapse

                    -  Must fulfill appropriate criteria above according to initial histology

        PATIENT CHARACTERISTICS:

          -  Neutrophil count ≥ 1,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Must have adequate renal function (creatinine clearance ≥ 60 mL/min)

          -  No prior malignancy except basal cell carcinoma

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Williams, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular choriocarcinoma and embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma and teratoma</keyword>
  <keyword>testicular choriocarcinoma</keyword>
  <keyword>testicular choriocarcinoma and yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma</keyword>
  <keyword>testicular seminoma</keyword>
  <keyword>testicular yolk sac tumor</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>recurrent extragonadal seminoma</keyword>
  <keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage IV extragonadal seminoma</keyword>
  <keyword>adult teratoma</keyword>
  <keyword>testicular immature teratoma</keyword>
  <keyword>testicular mature teratoma</keyword>
  <keyword>recurrent extragonadal germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Teratoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

